EU Pharmaceutical Exports Support Record 926,000 Jobs

Remarkable Growth In Employment

Exports of pharmaceutical products from the European Union to non-EU markets supported 926,000 jobs in 2023, marking a record level. This corresponds to 4.3 per mille of total employment across the EU and reflects the sector’s role in the broader economic structure.

Direct And Indirect Economic Impact

Within this total, the core pharmaceutical sector accounted for 325,000 jobs. An additional 601,000 positions were supported across related industries, indicating the extent of indirect employment linked to export activity and supply chains.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

A Steady Climb Since 2010

Since 2010, the number of jobs tied to pharmaceutical exports has consistently increased from 504,000 to the current record. During this period, employment related to these exports nearly doubled, with the workforce share growing from 2.6 to 4.3 per mille.

Role Of Key Trade Partners

Trade with the United States emerged as the most significant factor, supporting 275,000 EU jobs in 2023. Switzerland and China followed closely, sustaining 104,000 and 103,000 jobs respectively. The United Kingdom and Japan also remained significant partners, supporting 51,000 and 42,000 jobs.

Long-Term Trends By Market

Since 2010, employment growth has been concentrated among several major trading partners. The United States accounted for an increase of 147,000 jobs, followed by China with 91,000 and Switzerland with an additional 38,000 jobs over the same period.

Conclusion

The data illustrate how pharmaceutical exports contribute to employment across both core and related sectors. They also show how trade with key global markets continues to shape job creation within the European Union.

The Future Forbes Realty Global Properties

A New Twitter-Inspired Social Network Is Taking Shape

by News Editor

August 27, 2026

A new social network called Twitter.now is entering the market, with a founding team that includes former Twitter trademark counsel Stephen Coates. The service is being developed by startup Operation Bluebird.

As Ars Technica reported, X sued the company last year and asked a Delaware judge to block the launch. Operation Bluebird argued in a petition that X had abandoned trademarks including “Twitter” and “Tweet.”

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Coates has said the project is not an attempt to recreate the original Twitter. In a LinkedIn post, he described the platform as a new public space focused on trust, transparency and user choice.

AI System To Rate Posts

Twitter.now is currently being tested, with early access priced at $20. Its main feature is VERA, an AI system designed to evaluate posts, verify claims and provide sources and context.

Posts receive a trust score, with users eventually able to set a minimum score to filter their feeds. The company says this approach will give people more control over what they see instead of leaving those decisions entirely to an algorithm.

Moderation Remains A Challenge

Scaling moderation will be one of the platform’s biggest tests. Social networks have repeatedly struggled with content moderation as their communities grow, and newer platforms such as Bluesky have faced similar criticism.

Operation Bluebird says VERA will form the basis of its moderation and verification system. A second version is already planned, with expanded tools that would let users set a specific trust threshold for the posts appearing in their feeds.

For now, Twitter.now remains in an early testing phase, combining the familiarity of the Twitter name with an AI-driven approach to evaluating online information.

Breaking news